

Post Operative Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-04-28 | 111 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Post Operative Pain Management Market size is estimated at USD 42.80 billion in 2025, and is expected to reach USD 56.71 billion by 2030, at a CAGR of 5.79% during the forecast period (2025-2030).

Factors fueling the market's growth are the growing number of surgical procedures, the rising number of emergency hospital visits, the increasing demand for non-opioid-based analgesics, and the increasing focus on palliative care.

The growing number of surgical procedures drives the demand for post-operative pain management medications. For instance, according to the Canadian Institutes of Health Information data published in September 2023, in 2021-2022, Canada witnessed over 117,000 hip and knee replacements, marking a 5.9% increase from the preceding year. However, this figure remained below the pre-COVID-19 annual average. With such a huge increase in the number of surgeries performed across several countries, the market for post-operative pain management drugs is expected to exhibit substantial growth, as these medications play a crucial role in managing the pain caused by surgical procedures.

A study published in PubMed Central in January 2022 stated that, according to research conducted by the US Institute of Medicine in June 2022, post-operative pain was a common but often undertreated disease, with 80% of surgery patients experiencing post-operative pain and less than half of these patients reporting appropriate pain control. Furthermore, the study stated that, according to a nationwide survey, 39% of post-operative patients felt severe to terrible pain. Such unmet needs greatly highlight the need for post-operative pain management drugs to optimize palliative care among the patient population, thereby providing lucrative opportunities to prominent players within the market.

Additionally, strategic initiatives by the market players, such as product launches and research and development activities in the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

field of pain management, are expected to boost the market's growth. For instance, in April 2022, Assiut University started a trial to evaluate the population pharmacokinetics and pharmacodynamics of rectal dexmedetomidine niosomes for post-operative analgesia in pediatric cancer patients undergoing bone marrow biopsy and aspiration compared to the intravenous and rectal plain formulation.

In April 2022, Acadia Pharmaceuticals Inc. announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scored over 24 hours between the ACP-044 1600 mg once daily, the ACP-044 400 mg four times daily, and the placebo treatment arms, was not met.

Thus, factors such as the rising number of surgical procedures and strategic initiatives by market players are expected to boost market growth over the forecast period. However, concerns about the overuse of opioids are a major factor restraining the market's growth.

Post Operative Pain Management Market Trends

The Non-steroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Hold a Significant Share of the Market

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold a significant market share by drug class. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain, reduce inflammation, and bring down high body temperatures.

The major factors fueling the segment's growth are the implementation of strategic initiatives by the market players, the growing demand for NSAIDs owing to their advantages over other drugs, and the increasing number of surgical procedures. For instance, in March 2022, Health Canada issued a Notice of Compliance (NOC) to commercialize Heron Therapeutics' ZYNRELEF (bupivacaine, which is an amide local anesthetic, and meloxicam, which is a non-steroidal anti-inflammatory drug (NSAID) extended-release solution) for instillation into the surgical wound for post-operative analgesia after a bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.

In March 2024, Eyenovia, in collaboration with its Taiwan-based partner, Formosa Pharmaceuticals, disclosed the FDA's approval of its clobetasol propionate 0.05% eye drops. These drops are meant to treat post-operative inflammation and pain following eye surgery.

Thus, the segment is expected to grow significantly over the forecast period due to the various strategic activities by the key players and the rise in acceptance of NSAIDs for post-operative pain management.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

The United States is expected to hold a significant share of the market in North America. The major factors bolstering the market's growth are the growing number of surgical procedures, the surge in awareness regarding post-operative pain management drugs, the increasing number of product approvals, and the rising focus on palliative care.

The increase in the number of surgeries in the country is expected to propel the growth of the market. For instance, Cedars-Sinai data updated in January 2022 showed that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass or bypass surgery, was the most common type of heart surgery. More than 300,000 people in the United States have successful bypass surgery each year. Such statistics are likely to increase the demand for post-operative pain management medications within the country, thereby boosting the market's growth.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Several guidelines and recommendations have been put forward by the healthcare authorities in the region, which is contributing to market growth. For instance, in March 2024, the American Academy of Orthopaedic Surgeons released updated guidelines for the treatment of hip osteoarthritis, which mentioned that pharmacologically managing hip osteoarthritis (OA) often involves the moderate recommendation of intra-articular corticosteroids. Additionally, intra-articular corticosteroids improve short-term function and reduce pain in patients with symptomatic hip OA.

Thus, owing to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

Post Operative Pain Management Industry Overview

The post-operative pain management market is fragmented, with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Pfizer Inc., AbbVie, GlaxoSmithKline PLC, Heron Therapeutics, and AFT Pharmaceuticals.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
 - 4.2.1 Growing Number of Surgical Procedures
 - 4.2.2 Increasing Demand for Non-Opioid Based Analgesics
 - 4.2.3 Increasing Focus Towards Palliative Care
- 4.3 Market Restraints
 - 4.3.1 Concerns Pertaining to the Overuse of Opioids
- 4.4 Porter's Five Forces Analysis
 - 4.4.1 Bargaining Power of Buyers/Consumers
 - 4.4.2 Bargaining Power of Suppliers
 - 4.4.3 Threat of New Entrants
 - 4.4.4 Threat of Substitute Products
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value -USD)

- 5.1 By Drug Class

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.1 Opioids
- 5.1.2 Non-steroidal anti-inflammatory drugs (NSAIDS)
- 5.1.3 Cyclooxygenase-2-selective inhibitors (COX-2) inhibitors
- 5.1.4 Other Drug Classes
- 5.2 By Route of Administration
 - 5.2.1 Injectable
 - 5.2.2 Oral
 - 5.2.3 Topical
 - 5.2.4 Other Routes of Administration
- 5.3 By Distribution Channel
 - 5.3.1 Hospital Pharmacies
 - 5.3.2 Retail Pharmacies
 - 5.3.3 Other Distribution Channels
- 5.4 Geography
 - 5.4.1 North America
 - 5.4.1.1 United States
 - 5.4.1.2 Canada
 - 5.4.1.3 Mexico
 - 5.4.2 Europe
 - 5.4.2.1 Germany
 - 5.4.2.2 United Kingdom
 - 5.4.2.3 France
 - 5.4.2.4 Italy
 - 5.4.2.5 Spain
 - 5.4.2.6 Rest of Europe
 - 5.4.3 Asia-Pacific
 - 5.4.3.1 China
 - 5.4.3.2 Japan
 - 5.4.3.3 India
 - 5.4.3.4 Australia
 - 5.4.3.5 South Korea
 - 5.4.3.6 Rest of Asia-Pacific
 - 5.4.4 Middle East and Africa
 - 5.4.4.1 GCC
 - 5.4.4.2 South Africa
 - 5.4.4.3 Rest of Middle East and Africa
 - 5.4.5 South America
 - 5.4.5.1 Brazil
 - 5.4.5.2 Argentina
 - 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
 - 6.1.1 AbbVie (Allergan)
 - 6.1.2 Heron Therapeutics
 - 6.1.3 Cali Biosciences
 - 6.1.4 Innocoll

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.5 Bayer AG
- 6.1.6 Haleon PLC (GSK)
- 6.1.7 Pacira Pharmaceuticals Inc.
- 6.1.8 Johnson & Johnson (Janssen Pharmaceuticals)
- 6.1.9 AFT Pharmaceuticals
- 6.1.10 Alembic Pharmaceuticals
- 6.1.11 Cipla Inc. (InvaGen Pharmaceuticals Inc.)
- 6.1.12 SiteOne Therapeutics
- 6.1.13 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Post Operative Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-04-28 | 111 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

